Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05501756 · ClinicalTrials.gov registry record · Phase 2
Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation
A Phase 2 study of Allogeneic Hematopoietic Cell Transplantation, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 60
- Enrollment target
- 1
- Study location
NCT05501756 is a Phase 2 study of Allogeneic Hematopoietic Cell Transplantation that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 60 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05501756, a Phase 2 study of Allogeneic Hematopoietic Cell Transplantation, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 60 participants
- Enrollment target
- 1
- Study location
Study Summary
Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal therapeutic window of 0.15-0.9 ug/mL.
Conditions Studied
Interventions
- DRUG Alemtuzumab
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2023-01-11 |
| Est. Completion | 2028-08-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05501756
The ClinicalTrials.gov registry entry for NCT05501756 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Allogeneic Hematopoietic Cell Transplantation appearing as the primary indexed condition, and to 1 intervention - of which Alemtuzumab is the first listed.
NCT05501756 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT05501756 about?
NCT05501756 is a clinical study titled "Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation". Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the...
What is the current status of trial NCT05501756?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 60 participants. The study started on 2023-01-11. Estimated completion is 2028-08-31.
What conditions does trial NCT05501756 study?
This clinical trial studies the following conditions: Allogeneic Hematopoietic Cell Transplantation.
What interventions are being tested in trial NCT05501756?
The interventions under investigation include: Alemtuzumab (DRUG).
Who is sponsoring clinical trial NCT05501756?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05501756 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Allogeneic Hematopoietic Cell Transplantation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.